Giovanni Catalano , Laura Alaimo , Odysseas P. Chatzipanagiotou , Zayed Rashid , Jun Kawashima , Andrea Ruzzenente , Federico Aucejo , Hugo P. Marques , Joao Bandovas , Tom Hugh , Nazim Bhimani , Shishir K. Maithel , Minoru Kitago , Itaru Endo , Timothy M. Pawlik
{"title":"胆囊癌复发模式及复发后生存预测。","authors":"Giovanni Catalano , Laura Alaimo , Odysseas P. Chatzipanagiotou , Zayed Rashid , Jun Kawashima , Andrea Ruzzenente , Federico Aucejo , Hugo P. Marques , Joao Bandovas , Tom Hugh , Nazim Bhimani , Shishir K. Maithel , Minoru Kitago , Itaru Endo , Timothy M. Pawlik","doi":"10.1016/j.gassur.2025.101997","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Gallbladder cancer (GBC) is associated with a poor prognosis. Recurrence patterns and their effect on survival remain ill-defined. This study aimed to analyze recurrence patterns and develop a machine learning (ML) model to predict survival after recurrence (SAR) of GBC.</div></div><div><h3>Methods</h3><div>Patients who underwent curative-intent resection of GBC between 1999 and 2022 were identified using an international database. An Extreme Gradient Boosting ML model to predict SAR was developed and validated.</div></div><div><h3>Results</h3><div>Among 348 patients, 110 (31.6%) developed disease recurrence during follow-up. The most common recurrence site was local (29.1%), followed by multiple site (26.4%), liver (21.8%), peritoneal (18.2%), and lung (0.05%). The median SAR was the longest in patients with lung recurrence (36.0 months), followed by those with local recurrence (15.7 months). In contrast, patients with peritoneal (8.9 months), liver (8.5 months), or multiple-site (6.4 months) recurrence had a considerably shorter SAR. Patients with multiple-site recurrence had a worse SAR than individuals with single-site recurrence (6.4 vs 11.10 months, respectively; <em>P</em> =.014). The model demonstrated good performance in the evaluation and bootstrapping cohorts (area under the receiver operating characteristic curve: 71.4 and 71.0, respectively). The most influential variables were American Society of Anesthesiologists classification, local recurrence, receipt of adjuvant chemotherapy, American Joint Committee on Cancer T and N categories, and developing early disease recurrence (<12 months). To enable clinical applicability, an easy-to-use calculator was made available (<span><span>https://catalano-giovanni.shinyapps.io/SARGB</span><svg><path></path></svg></span>).</div></div><div><h3>Conclusion</h3><div>Except for lung recurrence, SAR for GBC was poor. A subset of patients with less aggressive disease biology may have favorable SAR. ML-based SAR prediction may help individuate candidates for curative re-resection when feasible.</div></div>","PeriodicalId":15893,"journal":{"name":"Journal of Gastrointestinal Surgery","volume":"29 4","pages":"Article 101997"},"PeriodicalIF":2.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recurrence patterns and prediction of survival after recurrence for gallbladder cancer\",\"authors\":\"Giovanni Catalano , Laura Alaimo , Odysseas P. Chatzipanagiotou , Zayed Rashid , Jun Kawashima , Andrea Ruzzenente , Federico Aucejo , Hugo P. Marques , Joao Bandovas , Tom Hugh , Nazim Bhimani , Shishir K. Maithel , Minoru Kitago , Itaru Endo , Timothy M. Pawlik\",\"doi\":\"10.1016/j.gassur.2025.101997\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Gallbladder cancer (GBC) is associated with a poor prognosis. Recurrence patterns and their effect on survival remain ill-defined. This study aimed to analyze recurrence patterns and develop a machine learning (ML) model to predict survival after recurrence (SAR) of GBC.</div></div><div><h3>Methods</h3><div>Patients who underwent curative-intent resection of GBC between 1999 and 2022 were identified using an international database. An Extreme Gradient Boosting ML model to predict SAR was developed and validated.</div></div><div><h3>Results</h3><div>Among 348 patients, 110 (31.6%) developed disease recurrence during follow-up. The most common recurrence site was local (29.1%), followed by multiple site (26.4%), liver (21.8%), peritoneal (18.2%), and lung (0.05%). The median SAR was the longest in patients with lung recurrence (36.0 months), followed by those with local recurrence (15.7 months). In contrast, patients with peritoneal (8.9 months), liver (8.5 months), or multiple-site (6.4 months) recurrence had a considerably shorter SAR. Patients with multiple-site recurrence had a worse SAR than individuals with single-site recurrence (6.4 vs 11.10 months, respectively; <em>P</em> =.014). The model demonstrated good performance in the evaluation and bootstrapping cohorts (area under the receiver operating characteristic curve: 71.4 and 71.0, respectively). The most influential variables were American Society of Anesthesiologists classification, local recurrence, receipt of adjuvant chemotherapy, American Joint Committee on Cancer T and N categories, and developing early disease recurrence (<12 months). To enable clinical applicability, an easy-to-use calculator was made available (<span><span>https://catalano-giovanni.shinyapps.io/SARGB</span><svg><path></path></svg></span>).</div></div><div><h3>Conclusion</h3><div>Except for lung recurrence, SAR for GBC was poor. A subset of patients with less aggressive disease biology may have favorable SAR. ML-based SAR prediction may help individuate candidates for curative re-resection when feasible.</div></div>\",\"PeriodicalId\":15893,\"journal\":{\"name\":\"Journal of Gastrointestinal Surgery\",\"volume\":\"29 4\",\"pages\":\"Article 101997\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Gastrointestinal Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1091255X25000563\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastrointestinal Surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1091255X25000563","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:胆囊癌(GBC)预后较差。复发模式及其对生存的影响仍不明确。我们试图分析复发模式,并开发一种机器学习(ML)模型来预测GBC复发后的生存(SAR)。方法:在这项队列研究中,使用国际数据库确定1999年至2022年间接受治疗性GBC切除术的患者。开发并验证了用于预测SAR的XGBoost (Extreme Gradient-Boosting) ml模型。结果:348例患者中,110例(31.6%)在随访期间出现疾病复发。最常见的复发部位是局部(29.1%),其次是多部位(26.4%)、肝脏(21.8%)、腹膜(18.2%)和肺部(0.05%)。肺复发患者的平均生存期最长(36.0个月),其次是局部复发患者(15.7个月);相比之下,腹膜(8.9个月)、肝脏(8.5个月)和多部位复发(6.4个月)患者的SAR明显较短。值得注意的是,多部位复发患者的SAR明显较差(分别为6.43个月和11.10个月;p = 0.014)。该模型在评价和bootstrapping队列中表现良好(AUC分别为71.4和71.0)。影响最大的变量为ASA (American Society of Anesthesiologists)分级、局部复发、是否接受辅助化疗、AJCC (American Joint Committee on Cancer) T和N分类、是否出现早期疾病复发(结论:除肺部复发外,GBC的SAR较差。一小部分侵袭性较小的患者可能具有良好的SAR。基于ml的SAR预测可能有助于在可行的情况下个体化治疗性再切除的候选人。
Recurrence patterns and prediction of survival after recurrence for gallbladder cancer
Background
Gallbladder cancer (GBC) is associated with a poor prognosis. Recurrence patterns and their effect on survival remain ill-defined. This study aimed to analyze recurrence patterns and develop a machine learning (ML) model to predict survival after recurrence (SAR) of GBC.
Methods
Patients who underwent curative-intent resection of GBC between 1999 and 2022 were identified using an international database. An Extreme Gradient Boosting ML model to predict SAR was developed and validated.
Results
Among 348 patients, 110 (31.6%) developed disease recurrence during follow-up. The most common recurrence site was local (29.1%), followed by multiple site (26.4%), liver (21.8%), peritoneal (18.2%), and lung (0.05%). The median SAR was the longest in patients with lung recurrence (36.0 months), followed by those with local recurrence (15.7 months). In contrast, patients with peritoneal (8.9 months), liver (8.5 months), or multiple-site (6.4 months) recurrence had a considerably shorter SAR. Patients with multiple-site recurrence had a worse SAR than individuals with single-site recurrence (6.4 vs 11.10 months, respectively; P =.014). The model demonstrated good performance in the evaluation and bootstrapping cohorts (area under the receiver operating characteristic curve: 71.4 and 71.0, respectively). The most influential variables were American Society of Anesthesiologists classification, local recurrence, receipt of adjuvant chemotherapy, American Joint Committee on Cancer T and N categories, and developing early disease recurrence (<12 months). To enable clinical applicability, an easy-to-use calculator was made available (https://catalano-giovanni.shinyapps.io/SARGB).
Conclusion
Except for lung recurrence, SAR for GBC was poor. A subset of patients with less aggressive disease biology may have favorable SAR. ML-based SAR prediction may help individuate candidates for curative re-resection when feasible.
期刊介绍:
The Journal of Gastrointestinal Surgery is a scholarly, peer-reviewed journal that updates the surgeon on the latest developments in gastrointestinal surgery. The journal includes original articles on surgery of the digestive tract; gastrointestinal images; "How I Do It" articles, subject reviews, book reports, editorial columns, the SSAT Presidential Address, articles by a guest orator, symposia, letters, results of conferences and more. This is the official publication of the Society for Surgery of the Alimentary Tract. The journal functions as an outstanding forum for continuing education in surgery and diseases of the gastrointestinal tract.